Tocagen (Tocagen) Other Income (Expense) : $-0.63 Mil (TTM As of Mar. 2020)

View and export this data going back to 2017. Start your Free Trial

What is Tocagen Other Income (Expense)?

Tocagen's other income expense for the Tocagen's pretax income for the three months ended in Mar. 2020 was $-0.89 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2020 was $-0.63 Mil.

Tocagen Other Income (Expense) Historical Data

The historical data trend for Tocagen's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tocagen Other Income (Expense) Chart

Tocagen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Other Income (Expense)

0.11

0.05

0.04

-0.01

0.25

Tocagen Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Other Income (Expense)	Get a 7-Day Free Trial													-	-	-	0.25	-0.89

Tocagen Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63 Mil.

Tocagen (NAS:TOCA) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Tocagen (Tocagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tocagen Inc (NAS:TOCA) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4242 Campus Point Court, Suite 500, San Diego, CA, USA, 92121

Website

http://www.tocagen.com

Tocagen Inc is a clinical-stage, cancer-selective gene therapy company. It is focused on developing product candidates designed to activate a patient's immune system against their own cancer from within. The company's cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Tocagen is developing product candidate, Toca 511 and Toca FC, for the treatment of recurrent high grade glioma, or HGG, a brain cancer with limited treatment options, low survival rates and, therefore, a significant unmet medical need. Geographically, the activities are carried out through United States.